Form D · Biotechnology
Marea Therapeutics, Inc.
San Francisco, CA · CIK 0002027714
Offering snapshot reported Jun 24, 2024 · SEC filing
- Reported sold
- $65.4M Offering amount: $160M
- Investors reported
- 10 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jun 11, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jun 24, 2024 | Initial | $65,418,629 | No comparison | 10 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-516752
Source: Form D, filed Jun 24, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Antoine Boulanger | Director |
| Jung Choi | Director |
| Chris Garabedian | Director |
| Christine Garrett | Executive |
| Mark Joing | Executive |
| Maha Katabi | Director |
| Josh Lehrer | Director, Executive |
| Ted Love | Director |
| Caitlin Murray | Executive |
| Aaron Royston | Director |
| Jeff Tong | Director |
| Ethan Weiss | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
135 Mississippi Street
San Francisco, CA, 94107
San Francisco, CA, 94107